Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  BioPharma  /  Biophytis, de nieuwe raket?

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Biophytis, de nieuwe raket?

64 Posts
Pagina: «« 1 2 3 4 »» | Laatste | Omlaag ↓
  12. Small_first-Steps 6 november 2020 09:52
    Ben vorige week ingestapt in dit aandeel. Na een flinke lift en daarna een daling (GAK 0,72) hebben we gisteren wel een hele vreemde stijging gezien op het einde van de dag...
    Blijf voorlopig rustig zitten en hopen op mooi nieuws om het aandeel verder omhoog te stuwen
  19. vantodim1970 11 december 2020 10:42
    Deze keer wel een stijging op nieuws, dit staat op de website:

    Biophytis - First Patient Enrolled in France in COVA, an
    International Phase 2/3 Clinical Trial with Sarconeos (BIO101)
    for the Treatment of COVID-19 Related Respiratory Failure

    First Patient Dosed at La Pitié-Salpêtrière University Hospital in Paris

    Total of eight centers authorized by French National Health Agency
    (ANSM) for patient recruitment in France

    Paris, (France), Cambridge (Massachusetts, United States), December 11, 2020, 8:00 a.m. CET
    - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused
    on the development of therapeutics that slow the degenerative processes associated with
    aging and improve functional outcomes for patients suffering from age-related diseases,
    including severe respiratory failure in patients suffering from COVID-19, today announces that
    the first French patient has been dosed at La Pitié-Salpêtrière University Hospital, Paris, in
    COVA. The COVA study is a Phase 2/3 clinical trial with Sarconeos (BIO101) for the treatment
    of patients with COVID-19-related respiratory failure. Dr. Capucine Morelot-Panzini, Professor
    of Pulmonology at the Pitié-Salpêtrière University Hospital in Paris is the Principal Investigator
    of COVA in France.
    In addition to the two first centers at the Pitié-Salpêtrière University Hospital in Paris, Biophytis
    also received approval from the French National Agency for Medicines and Health Products
    Safety (ANSM) this month to open six new centers in France, among which Centre Hospitalier
    Rene Dubos and Centre Hospitalier d’Argenteuil in the Paris Region, bringing the total to eight
    centers planned to recruit COVID-19 patients in France.
    A total of 17 centers are now actively recruiting in Belgium, Brazil, France and the US among a
    targeted number of around thirty to be opened for the second part of the COVA study .
    The international COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global,
    multicentric, double-blind, placebo-controlled, group-sequential and adaptive two-part Phase
    2-3 study assessing Sarconeos (BIO101) in patients aged 45 and older, infected with SARS-CoV2.
    This pivotal clinical trial is being conducted in two parts, the first of which will assess the
    treatment safety and provide an indication of activity of Sarconeos (BIO101) in 50 hospitalized
    patients. The study is designed to evaluate the efficacy and the safety of Sarconeos (BIO101) as
    a treatment to prevent further deterioration of patients with COVID-19-related respiratory
    failure, which could otherwise require admission to the intensive care units and ventilation.
    Press release
    The first part of the study is a Phase 2 exploratory proof of concept study to provide preliminary
    data on the activity, safety and tolerability of Sarconeos (BIO101) in 50 hospitalized patients
    with severe respiratory manifestations related to COVID-19.
    The second part of the study will investigate the safety and efficacy of Sarconeos (BIO101) on
    the respiratory function of 310 COVID-19 patients (including the 50 patients from Part 1 of the
    study).
    Interim analysis and completion of full trial enrollment is expected in Q1 2021.
    Stanislas Veillet, CEO of Biophytis says: “I am very pleased that after all of the efforts by our
    teams over the past few months, we can now announce the first patient has been dosed at La
    Pitié-Salpêtrière Hospital and start our COVA clinical program in France. We have been working
    for many years with the team at La Pitié-Salpêtrière Hospital, which is linked with Sorbonne
    University’s medical school, a long-standing partner of Biophytis. The continued surge of COVID19 cases in France, Europe and the Americas and subsequent hospitalizations, re-emphasizes
    the emergency of finding innovative treatments against the pandemic (even while a vaccine is
    being rolled-out).
    We project enrollment of the 50 patients required for the first part of the study to complete in
    the coming weeks. Topline results of the COVA trial are expected in Q2 2021.”
    ***
    About BIOPHYTIS
    Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics
    that slow the degenerative processes associated with aging and improve functional outcomes for
    patients suffering from age-related diseases, including severe respiratory failure in patients suffering
    from COVID-19.
    Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being
    developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARAINT). It is also being studied in a clinical two-part Phase 2/3 study (COVA) for the treatment of severe
    respiratory manifestations of COVID-19 in Europe, Latin America and the US.
    A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne
    Muscular Dystrophy (DMD).
    The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares
    are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more
    information visit www.biophytis.com

    Disclaimer
    This press release contains forward-looking statements. While the Company considers its projections to
    be based on reasonable assumptions, these forward-looking statements may be called into question by
    Press release
    a number of hazards and uncertainties, so that actual results may differ materially from those
    anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to
    affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change
    from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Annual
    2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website
    (www.biophytis.com).
    This press release, and the information contained in it, does not constitute an offer to sell or subscribe,
    nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The
    elements contained in this communication may contain forward-looking information involving risks and
    uncertainties. The Company's actual achievements may differ materially from those anticipated in this
    information due to different risk and uncertainty factors. This press release was written in French and
    English; If there is a difference between the texts, the French version will prevail.
    Biophytis Contact for Investor Relations
    Evelyne Nguyen, CFO
    evelyne.nguyen@biophytis.com
    Media contact
    Citigate Dewe Rogerson
    Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
    biophytis@citigatedewerogerson.com
    Tel: +44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91
64 Posts
Pagina: «« 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 866,54 +0,14%
EUR/USD 1,0682 +0,10%
FTSE 100 7.878,75 +0,39%
Germany40^ 17.809,50 +0,22%
Gold spot 2.379,33 +0,78%
NY-Nasdaq Composite 15.683,37 -1,15%

Stijgers

Air Fr...
+2,59%
AZERION
+2,17%
ForFar...
+1,68%
ASML
+1,41%
ASR Ne...
+1,22%

Dalers

Pharming
-7,34%
Accsys
-2,84%
PostNL
-2,58%
Philip...
-1,11%
Sif Ho...
-1,09%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!